Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
St. Barnabas Medical Center
mi
from
Livingston, NJ
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
St. Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Buffalo General Hospital
mi
from
Buffalo, NY
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Buffalo General Hospital
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Mt. Sinai School of Medicine
mi
from
New York, NY
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Mt. Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
New York Presbyterian Hospital (Cornell)
mi
from
New York, NY
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
New York Presbyterian Hospital (Cornell)
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Westchester Medical Center
mi
from
Valhalla, NY
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Westchester Medical Center
mi
from
Valhalla, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
University Hospital of Cleveland
mi
from
Cleveland, OH
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
University Hospital of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Legacy Transplant Services
mi
from
Portland, OR
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Legacy Transplant Services
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Oregon Health and Science University
mi
from
Portland, OR
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Pinnacle Health at Harrisburg
mi
from
Harrisburg, PA
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Pinnacle Health at Harrisburg
mi
from
Harrisburg, PA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Methodist University Hospital - Memphis
mi
from
Memphis, TN
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Methodist University Hospital - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Baylor University Medical Center
mi
from
Dallas, TX
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Methodist Hospital Research Institute of Houston
mi
from
Houston, TX
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Methodist Hospital Research Institute of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
University of Utah Medical Center
mi
from
Salt Lake City, UT
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
University of Utah Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
Virginia Commonwealth University, School of Medicine
mi
from
Richmond, VA
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
Virginia Commonwealth University, School of Medicine
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
University of Washington Medical Center
mi
from
Seattle, WA
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated:  11/6/2015
University of Wisconsin Hospital
mi
from
Madison, WI
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Enrolling
Updated: 11/6/2015
University of Wisconsin Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Renal Allograft Tolerance Through Mixed Chimerism
Status: Enrolling
Updated:  11/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Renal Allograft Tolerance Through Mixed Chimerism
Status: Enrolling
Updated: 11/6/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
XM-One Study for Living Donor Program
XM-One Study for Living Donor Program
Status: Enrolling
Updated:  11/10/2015
University of Miami
mi
from
Miami, FL
XM-One Study for Living Donor Program
XM-One Study for Living Donor Program
Status: Enrolling
Updated: 11/10/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Lakewood, CO
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Orlando, FL
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Knoxville, TN
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1245.28.10016 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AR
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1245.28.10016 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.023 Boehringer Ingelheim Investigational Site
mi
from
Fremont, CA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.023 Boehringer Ingelheim Investigational Site
mi
from
Fremont, CA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.032 Boehringer Ingelheim Investigational Site
mi
from
Moreno Valley, CA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.032 Boehringer Ingelheim Investigational Site
mi
from
Moreno Valley, CA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1220.48.0018 Boehringer Ingelheim Investigational Site
mi
from
Oceanside, CA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1220.48.0018 Boehringer Ingelheim Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.025 Boehringer Ingelheim Investigational Site
mi
from
Salinas, CA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.025 Boehringer Ingelheim Investigational Site
mi
from
Salinas, CA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.033 Boehringer Ingelheim Investigational Site
mi
from
San Pedro, CA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.033 Boehringer Ingelheim Investigational Site
mi
from
San Pedro, CA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.024 Boehringer Ingelheim Investigational Site
mi
from
Wilmington, DE
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.024 Boehringer Ingelheim Investigational Site
mi
from
Wilmington, DE
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1245.25.10068 Boehringer Ingelheim Investigational Site
mi
from
Washington,
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1245.25.10068 Boehringer Ingelheim Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.128.1054 Boehringer Ingelheim Investigational Site
mi
from
Largo, FL
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.128.1054 Boehringer Ingelheim Investigational Site
mi
from
Largo, FL
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
205.452.01255 Boehringer Ingelheim Investigational Site
mi
from
Columbus, GA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
205.452.01255 Boehringer Ingelheim Investigational Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.018 Boehringer Ingelheim Investigational Site
mi
from
Springfield, MO
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.018 Boehringer Ingelheim Investigational Site
mi
from
Springfield, MO
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1220.48.0066 Boehringer Ingelheim Investigational Site
mi
from
Neptune, NJ
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1220.48.0066 Boehringer Ingelheim Investigational Site
mi
from
Neptune, NJ
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1218.61.01023 Boehringer Ingelheim Investigational Site
mi
from
Wilmington, NC
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1218.61.01023 Boehringer Ingelheim Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
205.452.01002 Boehringer Ingelheim Investigational Site
mi
from
Altoona, PA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
205.452.01002 Boehringer Ingelheim Investigational Site
mi
from
Altoona, PA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Pittsburgh, PA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.037 Boehringer Ingelheim Investigational Site
mi
from
Lancaster, SC
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.037 Boehringer Ingelheim Investigational Site
mi
from
Lancaster, SC
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1160.173.006 Boehringer Ingelheim Investigational Site
mi
from
Live Oak, TX
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1160.173.006 Boehringer Ingelheim Investigational Site
mi
from
Live Oak, TX
Click here to add this to my saved trials
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated:  11/12/2015
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Status: Enrolling
Updated: 11/12/2015
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials